2004 年 56 巻 2-4 号 p. 169-171
Considering that dialysis patients are often elderly, the onset risk of gastric mucosa disorder is increased in them. Therefore, the use of a selective cyclooxigenase (COX)-2 inhibitor that is expected to reduce the digestive disorders in the dialysis patients is of great significance. We investigated pharmacokinetics of meloxicam which is a selective COX-2 inhibitor approved in over 100 countries including Japan. Nine renal patients (4 males and 5 females) on hemodialysis were investigated. Single oral administration of meloxicam was conducted after supper the day before dialysis and plasma consentration was determined. The blood was taken at 1 hour, before start of dialysis. The meloxicam concentratio n was analysed by ultrafiltration. The mean plasma meloxicam concentration (meant-SD) at 1 hour before start of dialysis and at 1,4 and 48 hours after the start of dialysis were 541±168 ng/ml,532±153,512± 161,42± 72, respectively. The re sults indicated not significant changes in the plasma concentration at 1 and 4 hours after start of dialysis.